The efficacy of anti-IL-4/13 receptor monoclonal antibody on chronic prurigo
- Conditions
- chronic prurigo
- Registration Number
- JPRN-jRCTs031200073
- Lead Sponsor
- Tsuyoshi Namiki
- Brief Summary
In this study, two cases were successfully treated with dupilumab. Further research is needed to validate the effectiveness of dupilumab in the treatment of prurigo chronica multiformis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 2
1) a patient with chronic prurigo
2) a patient who was not improved by oral anti-histamine drug and topical steroid
3) a patient at age 20 or over
4) a patient who fully understand and agree to join this clinical study
5) outpatient
1) a patient orally administrated immune suppressants or high-dose steroid within three months
2) a patient who undergo UV photo therapy
3) a patinet who was treated with anti-IgE antibody within four months
4) a patient suffering from severe visceral diseases, autoimmune diseases, blood dosorders, and mental disorders
5) a patient who is pregnant or breast-feed
6) a patinet who is infected with parasite
7) a patient who is sensitive to this medication
6) a patient judged inadequate to this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method